Transenterix (TRXC) Earns Hold Rating from BTIG Research
Several other brokerages have also commented on TRXC. Ladenburg Thalmann Financial Services set a $5.00 price target on shares of Transenterix and gave the stock a buy rating in a report on Friday, October 20th. Stifel Nicolaus boosted their price target on shares of Transenterix from $3.75 to $4.00 and gave the stock a buy rating in a report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $2.61.
Shares of Transenterix (NYSEAMERICAN:TRXC) opened at $2.03 on Monday. Transenterix has a 1-year low of $0.45 and a 1-year high of $5.00.
An institutional investor recently raised its position in Transenterix stock. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 79,150 shares of the medical instruments supplier’s stock after purchasing an additional 37,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned approximately 0.05% of Transenterix worth $113,000 at the end of the most recent quarter.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.